Alterity Therapeutics Ltd
PRNAF- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001131343
In the last 90 days, Alterity Therapeutics Ltd insiders filed 1 open-market purchase and 0 sales; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Other share classesATHE
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Alterity Therapeutics Ltd insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 1 filing
- 1 insider, $23.8K in total
- Open-market sells
- 0 filings
- Insiders trading
- 1
- Net value
- +$23.8K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Alterity Therapeutics Ltd, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Marks Peter Ashley | Director | 191,340Indirect | Sep 8, 2026 | 1 |
| Stamler David Allen | Chief Executive Officer | – | Sep 8, 2026 | 1 |
| Gozlan Lawrence Bernard | Director | – | Jun 23, 2026 | 1 |
| Babarczy Julian Michael | Director | – | Jun 23, 2026 | 1 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 8, 2026 (view filing)7:01 PM ET | Aug 31 | 8 daysLate | Marks Peter AshleyDirector | PPurchase | +47.6K | $0.50 | +$23.8K | +33.1%191.3K after | |
| Sep 8, 2026 (view filing)7:01 PM ET | Aug 31 | 8 daysLate | Marks Peter AshleyDirector | PPurchase | −47.6K | $0.50 | −$23.8K | –0 after | DerivativeDuplicate filing |
| Sep 8, 2026 (view filing)6:52 PM ET | Aug 31 | 8 daysLate | Stamler David AllenChief Executive Officer | PPurchase | −47.6K | $0.50 | −$23.8K | –0 after | Derivative |